Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Research & Development (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Research & Development for 15 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 47.75% to $5.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $35.3 million through Dec 2025, down 4.14% year-over-year, with the annual reading at $35.3 million for FY2025, 4.13% down from the prior year.
  • Research & Development hit $5.1 million in Q4 2025 for Cardiff Oncology, down from $8.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $11.6 million in Q2 2025 to a low of $3.3 million in Q1 2021.
  • Historically, Research & Development has averaged $7.5 million across 5 years, with a median of $7.9 million in 2023.
  • Biggest five-year swings in Research & Development: soared 119.82% in 2022 and later crashed 47.75% in 2025.
  • Year by year, Research & Development stood at $5.8 million in 2021, then grew by 10.61% to $6.4 million in 2022, then rose by 20.51% to $7.8 million in 2023, then grew by 25.11% to $9.7 million in 2024, then plummeted by 47.75% to $5.1 million in 2025.
  • Business Quant data shows Research & Development for CRDF at $5.1 million in Q4 2025, $8.2 million in Q3 2025, and $11.6 million in Q2 2025.